Experimental and clinical data indicate that carboplatin is as effective as cisplatin in the treatment of ovarian cancer patients with advanced bulky disease. It has an improved toxicity profile with a low incidence of ototoxicity, neuropathy, and nephropathy. In the absence of severe myelosuppression, the dose of carboplatin should be escalated in patients who have good renal function. Over the next few years, carboplatin will either replace cisplatin, or will be easier to use in a dose-intensive fashion.
|Original language||English (US)|
|Number of pages||3|
|Journal||Seminars in Oncology|
|Issue number||4 SUPPL. 7|
|State||Published - Jan 1 1990|
ASJC Scopus subject areas